FOLLOWING widespread recalls of antacid therapy ranitidine (including leading originator brand Zantac), in the UK, Europe, Canada and the US, Aspen Pharmacare Australia has released a statement.
The company told Pharmacy Daily, "Following the TGA's latest advice regarding ranitidine products, Aspen Australia has begun a retail level recall on all Zantac products".
"Aspen Australia treats the quality of its products with utmost diligence and will continue to work closely with the TGA on this matter," a spokesperson said.
The TGA has confirmed its previously held position that the "additional risk posed by NDMA from ranitidine, at the levels identified to date, is considered to be very low" and "there is no immediate health risk" - see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Oct 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Oct 19